INDIANAPOLIS (February 10, 2021—Apria, Inc. (the company or Apria) announced today the pricing of its initial public offering of 7,500,000 shares of its common stock at a price to the public of $20.00 per share. The selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock. The shares are expected to begin trading on the Nasdaq Global Select Market on Feb.

ATLANTA (February 10, 2021)—The Health Care business of LexisNexis Risk Solutions has announced the release of its Top 100 Hospice and Home Health Agencies Rankings for 2020. The annual report provides hospice care and home health organizations visibility into industry rankings, market dynamics, standing among competitors, and the overall industry environment for potential M&A activity and growth for their business.  

FOOTHILL RANCH, Calif. (February 9, 2021)—Össur, a global innovator in prosthetic and non-invasive orthopaedic technologies, has implemented critical updates to its proprietary Empower Össur program, helping physician practices, durable medical equipment, and prosthetic and orthotic suppliers (DMEPOS) comply with new, federally mandated competitive bidding requirements for knee and back braces that went into effect on Jan. 1. 

SPARTANBURG, S.C. (February 9, 2021)—RedSail Technologies, LLC, is excited about the recent launch of the RedSail Hub. The new RedSail Hub is a centralized portal designed to provide QS/1 and Integra customers with relevant information in a timely, easily accessible way. This intuitive, in-depth, and customer-friendly platform provides content and materials relative to a pharmacy operation’s needs.

IRVINE, Calif. (February 8, 2021)—GoPAPfree, a homecare provider of oral appliance therapy for obstructive sleep apnea, announced the launch of their new product O2Vent Optima, a highly effective and more convenient alternative to CPAP therapy. This patented and exclusive appliance is the only device with integrated airway technology and increases the response rate to sleep apnea therapy by 40% compared to standard mouthguards.